Clinical Trials

Find a Trial

Trial Summary

Protocol No.CTMX-M-2009-001
StatusOPEN TO ACCRUAL
Principal InvestigatorO'Neil, Bert
ScopeNational
PhasePhase I/II
Age GroupAdult
TitleA Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
DescriptionThe purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • 18 years or older
  • Diagnosis of metastatic or locally advanced unresectable tumors
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesBrain and Nervous System
Breast - Female
Liver
Lung
Other Female Genital
Ovary
Prostate
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactAnne E. Younger, RNPhone: 317-274-0951
Pager: 317-312-1946
Email: anefoste@iupui.edu